business

Eli Lilly Strikes Up to $1.5B Deal to Buy Calytrix Bio

Eli Lilly agrees to acquire Calytrix Bio in a deal worth up to $1.5 billion, expanding its pipeline through another targeted biotech buy.

By SeekingAlpha

In Brief

Latest in Business

all →
business
Eli Lilly Strikes Up to $1.5B Deal to Buy Calytrix Bio
business
Rivian, Lucid, Scout CEOs Ditch Hope for Democrat EV Rescue
business
ChatGPT Can Now Buy Things for You Using Visa, Mastercard or Amex
business
NHL Team Values Jump 23% to $2.71B Average in 2026 Rankings

Stay informed.

One concise briefing, weekly. No spam.

By subscribing you agree to receive periodic communications. Unsubscribe anytime via the link in each message or our Unsubscribe page.